ALKS
Price
$40.85
Change
+$0.06 (+0.15%)
Updated
Sep 25 closing price
Capitalization
6.85B
31 days until earnings call
Intraday BUY SELL Signals
VTRS
Price
$17.83
Change
+$0.41 (+2.35%)
Updated
Sep 25 closing price
Capitalization
20.48B
43 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALKS vs VTRS

ALKS vs VTRS Comparison Chart in %
View a ticker or compare two or three
VS
ALKS vs. VTRS commentary
Sep 27, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a StrongBuy and VTRS is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
ALKS vs VTRS: Fundamental Ratings
ALKS
VTRS
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
12
Undervalued
PROFIT vs RISK RATING
1..100
5344
SMR RATING
1..100
8591
PRICE GROWTH RATING
1..100
5526
P/E GROWTH RATING
1..100
21
SEASONALITY SCORE
1..100
3750

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (12) in the null industry is significantly better than the same rating for ALKS (99) in the Biotechnology industry. This means that VTRS’s stock grew significantly faster than ALKS’s over the last 12 months.

VTRS's Profit vs Risk Rating (44) in the null industry is in the same range as ALKS (53) in the Biotechnology industry. This means that VTRS’s stock grew similarly to ALKS’s over the last 12 months.

ALKS's SMR Rating (85) in the Biotechnology industry is in the same range as VTRS (91) in the null industry. This means that ALKS’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's Price Growth Rating (26) in the null industry is in the same range as ALKS (55) in the Biotechnology industry. This means that VTRS’s stock grew similarly to ALKS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is in the same range as ALKS (2) in the Biotechnology industry. This means that VTRS’s stock grew similarly to ALKS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSVTRS
RSI
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
58%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
49%
Momentum
ODDS (%)
Bearish Trend 3 days ago
70%
Bullish Trend 3 days ago
72%
MACD
ODDS (%)
Bearish Trend 3 days ago
55%
Bullish Trend 3 days ago
72%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
64%
Bullish Trend 3 days ago
71%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
61%
Bullish Trend 3 days ago
67%
Advances
ODDS (%)
Bullish Trend 11 days ago
73%
Bullish Trend 3 days ago
74%
Declines
ODDS (%)
Bearish Trend 4 days ago
64%
Bearish Trend 18 days ago
63%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
70%
Bearish Trend 3 days ago
54%
Aroon
ODDS (%)
Bearish Trend 3 days ago
56%
Bullish Trend 3 days ago
69%
COMPARISON
Comparison
Sep 27, 2026
Stock price -- (ALKS: $40.85 vs. VTRS: $17.83)
Brand notoriety: ALKS and VTRS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALKS: 131% vs. VTRS: 112%
Market capitalization -- ALKS: $6.85B vs. VTRS: $20.48B
ALKS [@Pharmaceuticals: Generic] is valued at $6.85B. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $20.48B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $66.76B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 1 FA rating(s) are green while VTRS’s FA Score has 3 green FA rating(s).

  • ALKS’s FA Score: 1 green, 4 red.
  • VTRS’s FA Score: 3 green, 2 red.
According to our system of comparison, VTRS is a better buy in the long-term than ALKS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 4 TA indicator(s) are bullish while VTRS’s TA Score has 6 bullish TA indicator(s).

  • ALKS’s TA Score: 4 bullish, 5 bearish.
  • VTRS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, VTRS is a better buy in the short-term than ALKS.

Price Growth

ALKS (@Pharmaceuticals: Generic) experienced а -5.85% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was +5.19% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.49%. For the same industry, the average monthly price growth was -6.14%, and the average quarterly price growth was +42.31%.

Reported Earning Dates

ALKS is expected to report earnings on Oct 28, 2026.

VTRS is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+3.49% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
ALKS
Daily Signal:
Gain/Loss:
VTRS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FDD19.730.19
+0.97%
First Trust STOXX European Select Dividend Income Fund
BIV73.340.20
+0.27%
Vanguard Intermediate-Term Bond ETF (BIV)
BCTK31.050.08
+0.27%
Baron Technology ETF (BCTK)
TLTI42.05-0.02
-0.05%
NEOS Enhanced Income 20+ Year Treasury Bond ETF (TLTI)
FTOH7.92-0.05
-0.63%
Franklin Ohio Municipal Income ETF (FTOH)

ALKS and

Correlation & Price change

A.I.dvisor tells us that ALKS and NBIX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALKS and NBIX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALKS
1D Price
Change %
ALKS100%
+0.15%
NBIX - ALKS
31%
Poorly correlated
-0.39%
VTRS - ALKS
31%
Poorly correlated
+2.35%
ACET - ALKS
30%
Poorly correlated
+9.07%
AMRX - ALKS
28%
Poorly correlated
-0.18%
TEVA - ALKS
28%
Poorly correlated
-2.56%
More

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with AMRX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
+2.35%
AMRX - VTRS
43%
Loosely correlated
-0.18%
COLL - VTRS
36%
Loosely correlated
-0.49%
AMPH - VTRS
35%
Loosely correlated
-0.53%
TEVA - VTRS
34%
Loosely correlated
-2.56%
ELAN - VTRS
34%
Loosely correlated
-0.18%
More